PL1638559T3 - Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych - Google Patents

Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych

Info

Publication number
PL1638559T3
PL1638559T3 PL04767477T PL04767477T PL1638559T3 PL 1638559 T3 PL1638559 T3 PL 1638559T3 PL 04767477 T PL04767477 T PL 04767477T PL 04767477 T PL04767477 T PL 04767477T PL 1638559 T3 PL1638559 T3 PL 1638559T3
Authority
PL
Poland
Prior art keywords
pyrazolopyridines
treatment
individuals
improve
cognitive deficits
Prior art date
Application number
PL04767477T
Other languages
English (en)
Inventor
Fabien Schweighoffer
Laurent Desire
Annelies Resink
Magali Rouquette
Original Assignee
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa
Publication of PL1638559T3 publication Critical patent/PL1638559T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
PL04767477T 2003-06-27 2004-06-25 Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych PL1638559T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0307824A FR2856595B1 (fr) 2003-06-27 2003-06-27 Methodes et compositions pour le traitement de deficits cognitifs.
PCT/FR2004/001630 WO2005000302A1 (fr) 2003-06-27 2004-06-25 Utilisation de pyrazolopyridines pour le traitement de deficits cognitifs
EP04767477A EP1638559B1 (fr) 2003-06-27 2004-06-25 Utilisation de pyrazolopyridines pour le traitement de deficits cognitifs

Publications (1)

Publication Number Publication Date
PL1638559T3 true PL1638559T3 (pl) 2010-06-30

Family

ID=33515478

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04767477T PL1638559T3 (pl) 2003-06-27 2004-06-25 Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych

Country Status (15)

Country Link
US (1) US20060142326A1 (pl)
EP (1) EP1638559B1 (pl)
JP (1) JP5008976B2 (pl)
CN (1) CN100525764C (pl)
AT (1) ATE454147T1 (pl)
AU (1) AU2004251466B2 (pl)
CA (1) CA2528284C (pl)
DE (1) DE602004024992D1 (pl)
DK (1) DK1638559T3 (pl)
ES (1) ES2337255T3 (pl)
FR (1) FR2856595B1 (pl)
IL (1) IL172229A (pl)
PL (1) PL1638559T3 (pl)
PT (1) PT1638559E (pl)
WO (1) WO2005000302A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
FR2828693B1 (fr) † 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US7356544B2 (en) * 2003-06-30 2008-04-08 Giovanni Giunta Method and system for automatically relaying website information
US20070049608A1 (en) * 2005-08-24 2007-03-01 Fink Cynthia A Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977305A (en) * 1990-04-20 1999-11-02 Cold Spring Harbor Laboratories Cloning by complementation and related processes
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
AU4270596A (en) * 1994-12-23 1996-07-19 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
FR2753706B1 (fr) * 1996-09-20 1998-10-30 Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
EP1328261A2 (en) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
AU4878601A (en) * 2000-04-20 2001-11-07 Mitsubishi Corporation Aromatic amide compounds
EP1278749B1 (en) * 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
EP1383767A1 (en) * 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
IL147953A (en) * 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
WO2003076408A2 (en) * 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
DK1583541T3 (da) * 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese

Also Published As

Publication number Publication date
PT1638559E (pt) 2010-03-01
WO2005000302A1 (fr) 2005-01-06
ATE454147T1 (de) 2010-01-15
FR2856595B1 (fr) 2008-05-30
DE602004024992D1 (de) 2010-02-25
AU2004251466A1 (en) 2005-01-06
AU2004251466B2 (en) 2010-01-07
JP5008976B2 (ja) 2012-08-22
CA2528284A1 (fr) 2005-01-06
CN1812786A (zh) 2006-08-02
CA2528284C (fr) 2012-10-23
FR2856595A1 (fr) 2004-12-31
EP1638559A1 (fr) 2006-03-29
CN100525764C (zh) 2009-08-12
DK1638559T3 (da) 2010-04-19
EP1638559B1 (fr) 2010-01-06
HK1091657A1 (zh) 2007-01-26
US20060142326A1 (en) 2006-06-29
ES2337255T3 (es) 2010-04-22
IL172229A (en) 2013-10-31
JP2007520427A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
Kelley et al. Alzheimer's disease and mild cognitive impairment
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
MY145356A (en) Piperzine with or-substitution for glyt1
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005001483A3 (en) Methods for diagnisis and differential diagnosis of dementia disorders
WO2006047357A3 (en) Human ly6-big molecules and methods of use
MY135225A (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
MX2007001117A (es) Metodos para diagnosticar la enfermedad de alzheimer.
TW200612900A (en) The use of therapeutic and preventive action of l-3-n-butylphthalide on dementia, involving alzheimer's disease and vascular dementia